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Phthalates are ubiquitous environmental endocrine-disrupting chemicals suspected to 
interfere with developmental androgen action leading to adverse effects on male repro-
ductive function. Prenatal exposure studies in rodents show cryptorchidism, hypospa-
dias and reduced testicular volume (TV), testosterone and anogenital distance in males. 
It is postulated that there is a developmental window in utero when phthalate exposure 
has the most potent adverse effects. Some human studies show associations between 
prenatal phthalate exposure and reduced calculated “free” serum testosterone in infant 
boys and shorter anogenital distance. However, there are no data available yet which 
link antenatal exposure to long-term effects in men. We aimed to correlate antenatal 
phthalate exposure with adult TV, semen parameters and serum reproductive hormone 
concentrations. 913 men from the Western Australian (Raine) Pregnancy Cohort were 
contacted aged 20–22 years. 423 (56%) agreed to participate; 404 underwent testicular 
ultrasound examination; 365 provided semen samples, and reproductive hormones were 
measured in 384. Maternal antenatal serum phthalate metabolite measurements were 
available for 185 and 111 men, who provided serum and semen, respectively. Maternal 
serum collected at 18 and 34 weeks gestation, stored at −80°C, was pooled and ana-
lyzed for 32 phthalate metabolites by liquid chromatography-tandem mass spectrometry. 
TV was calculated, semen analysis performed by WHO approved methods, and serum 
concentrations of gonadotrophins, inhibin B, and testosterone measured. Eleven phthal-
ate metabolites were detected. Primary and secondary metabolites of di-(2-ethyl-hexyl) 
phthalate (DEHP) and di-iso-nonyl phthalate (DiNP) were positively correlated. After cor-
rection for adult height, BMI, presence of a varicocele and exposure to maternal smoking 
mono-iso-nonyl phthalate (MiNP) (r = −0.22) and sums of DEHP and DiNP metabolites 
(r = −0.24) and the sum of the metabolites of the high molecular weight phthalates 
(r = −0.21) were negatively correlated with TV (all p < 0.05). After adjustment for BMI 
adult serum total testosterone was positively associated with exposure to the following 
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antenatal serum phthalate metabolites: mono-(2-ethylhexyl) phthalate (r = 0.26), MiNP 
(r = 0.18), the sum of metabolites for DEHP (r = 0.21) and DiNP (r = 0.18), and the sum 
of high molecular phthalates (r = 0.20) (p = 0.0005 to p = 0.02). Given sample size, stor-
age duration and confounding through postnatal exposures, further studies are required.
Keywords: raine, endocrine disrupter, testicular volume, testosterone, sperm count
inTrODUcTiOn
There is increasing concern about the potential for the environ-
ment to impact on reproductive health. We have previously 
reported that a high proportion of healthy 18- to 20–year-old 
European and Australian men had semen quality below the 
WHO reference ranges (1), Jorgensen et  al. (2). Furthermore 
a previous study (2000–2002) of older fertile Australian men 
(average 35  years) found significantly higher sperm counts 
than those in our recent study of young Australian men from 
a birth cohort (3). This raises the question whether a change in 
semen quality may have occurred in parallel with the increasing 
incidence of undescended testis, hypospadias and testicular 
cancer reported in some countries, including Australia (4–8). 
As registry data of testicular cancer is generally robust, and as 
the incidence of the disease has increased twofold to fourfold 
over several generations, it would appear plausible that some 
form of environmental exposures, or change in lifestyle factors, 
may have a role in their pathogenesis. It has been suggested that 
testicular cancer, cryptorchidism, hypospadias and a decrease 
in semen quality may be symptoms of a testicular dysgenesis 
syndrome (TDS) due to fetal endocrine disrupter exposures 
(6). The TDS hypothesis proposes that as a result of abnormal 
testicular development, a secondary abnormality in Leydig 
and/or Sertoli cells results during male sexual differentiation, 
leading to abnormal reproductive development, reduced sperm 
counts and testicular cancer in later life (7, 9). However, the 
existence of TDS as a unitary entity has been doubted (10, 11), 
and a systematic review concluded that, currently there was 
insufficient evidence to link prenatal exposures with adult male 
reproductive disorders (12).
Phthalates are diesters of phthalic acid and are widely used 
in industry and personal care products with exposure through 
the skin (13), mouth, or through inhalation.1 Phthalates are 
chemicals with endocrine-disrupting properties (14–16) and 
can cross the placenta to reach the developing fetus (17). They 
are detectable in amniotic fluid (18), and may reach the new-
born via breast milk leading to compensated hypogonadism 
(19). The use of some phthalates [i.e., DnBP, DiBP, BBzP and di- 
(2-ethyl-hexyl) phthalate (DEHP)], in cosmetics and toys 
within the European Union, has since been restricted. The TDS 
hypothesis has some support from animal studies where fetal 
exposure to phthalates may induce similar features, including 
dysgenesis of testicles and compensated hypogonadism (20). 
Additionally, there are reports of a decrease in the anogenital 
distance (a marker of androgen action), at 2  years of age, in 
1 www.atsdr.cdc.go. (Accessed: August 1, 2017).
male infants exposed in utero to higher levels of phthalate meta-
bolites, as measured from maternal urine during pregnancy 
(21), although not confirmed by other studies (22, 23). The 
influence of the phthalate exposure, if significant, may vary 
according to the timing of the pregnancy exposure (24), and be 
dose dependent, as differences are not noted in populations with 
low phthalate exposure (22). However, little is known about the 
longer-term effects on reproductive health of men after ante-
natal phthalate exposures. Our study set out to determine any 
associations between antenatal serum concentrations of phtha-
late metabolites and markers of testicular function, via a correla-
tion analysis, in a cohort of men who have been recognized as a 
valid reference population (1, 25).
MaTerials anD MeThODs
The raine study
The West Australian Pregnancy Cohort (Raine) Study2 was 
designed to measure the relationships between early life events 
and subsequent health and behavior. The study recruited nearly 
3,000 women around 18 weeks gestation in 1989–1991 (26) over 
a total of 30 months. The 2,868 children (including 1,455 boys) 
born to 2,804 mothers were retained to form the Raine Study 
cohort. The cohort is unique because detailed antenatal, postna-
tal, and childhood measurements have been made. The women 
originally recruited in pregnancy were equally randomized to 
an intensive investigation where maternal blood samples were 
collected at 18 and 34/36  weeks of gestation (and stored in 
aliquots without thawing at −80°C), and fetal ultrasound meas-
urements were made. A maternal history of cigarette smoking 
was recorded prospectively at 18 and 34/36  weeks. A general 
cohort follow-up was undertaken at ages 1, 2, 3, 5, 8, 10, 14, 
17, 20, and 22 years with the latest cohort including 1,433 men 
still alive, making it one of the largest and most closely followed 
prospective cohorts of pregnancy, childhood, and adolescence 
in the world. Even at 20 years of age the cohort remained rep-
resentative of the general Western Australian population (27). 
Ethical approval was obtained from the University of Western 
Australia Human Research Ethics Committee, and all partici-
pants provided informed written consent.
clinical assessment at 20 Years of age
All cohort members were invited to attend follow-up, which 
involved questionnaires, collection of anthropometric data 
(28), and collection of serum for analysis for testosterone, 
estradiol (E2) and estrone (E1), luteinizing hormone (LH), follicle 
2 www.rainestudy.org.au. (Accessed: August 1, 2017).
TaBle 1 | Phthalate diesters and their respective metabolites detected in 
maternal serum during pregnancy and sums of metabolites used for statistical 
analysis.
Phthalate diester human serum metabolite
Di-ethyl phthalate DEP Mono-ethyl phthalate MEP
Di-iso-butyl phthalate DiBP Mono-iso-butyl phthalate MiBP
Di-n-butyl phthalate DnBP Mono-n-butyl phthalate MnBP
Mono-(3-hydroxybutyl) 
phthalate
MHBPa
Butylbenzyl phthalate BBzP Mono-benzyl phthalate MBzP
Di-(2-ethyl-hexyl) phthalate DEHP Mono-(2-ethyl-hexyl) phthalate MEHP
Mono-(2-ethyl-5-carboxypentyl) 
phthalate
MECPPa
Mono-(2-carboxymethyl-hexyl) 
phthalate
MCMHPa
Di-octyl phthalate DOP Mono-3-carboxypropyl 
phthalate
MCPPa
Di-iso-nonyl phthalate DiNP Mono-iso-nonyl phthalate MiNP
Mono-carboxy-iso-octyl 
phthalate
MCiOPa
sums of phthalate metabolites
ΣMBP (i + n) Sum of MiBP and MnBP in ng/mL
ΣDEHPm Molar sum of MEHP, MCMHP, and MECPP 
expressed as DEHP in ng/mL
ΣDiNPm Molar sum of MiNP and MCIOP expressed as 
DiNP in ng/mL
ΣDEHPm + DiNPm Molar sum of MEHP, MCMHP, MECPP, MiNP, 
MCiOP expressed as MEHP in ng/mL
ΣLMW phth.m Molar sum of MEP, MiBP, MnBP, and MHBP 
expressed as MEP in ng/mL
ΣHMW phth.m Molar sum of MBzP, MEHP, MCMHP, MECPP, 
MCPP, MiNP, MCiOP, and MiDP expressed as 
MEHP in ng/mL
Σall phth.m Molar sum of MEP, MiBP, MnBP, MHBP, MBzP, 
MEHP, MCMHP, MECPP, MCPP, MiNP, MCiOP, 
and MiDP expressed as MEHP in ng/mL
aSecondary metabolite, all other metabolites are primary metabolites.
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stimulating hormone (FSH), and inhibin B (inhB) concentrations. 
A testicular ultrasound examination was performed (at King 
Edward Memorial Hospital) and a semen sample analyzed at the 
IVF unit (Fertility Specialists of Western Australia) as previously 
reported (1).
Semen samples were analyzed as per WHO semen manual 
guidelines (29) including sperm concentrations (million per 
milliliter), total sperm output (million per ejaculate), and 
total progressively motile sperm (TMS) being the seminal 
volume ×  concentration ×  motility (%A grade +  %B grade) 
and sperm morphology according to strict WHO criteria. The 
sperm chromatin structural assay (SCSA) was performed as 
described (30) with slight modifications. The DNA fragmenta-
tion index represents the percentage of sperm within the sample 
with fragmented or damaged DNA. Serum inhB concentration 
was measured by Gen II ELISA (Beckman Coulter, Inc., Brea, 
CA, USA), which had a limit of detection of 2.6 pg/mL. LH and 
FSH were determined in duplicate by ELISA (IBL International, 
Hamburg, Germany). The limit of detection of the LH assay was 
1.3  IU/L (calibrated against WHO IRP 80/552), while for FSH 
assay it was 1 IU/L (calibrated against NIBSC 92/510). The intra-
assay precision (CV) of the ELISAs ranged from 8 to 11% based 
on the mean values for low and high value quality control samples 
from n = 16–17 assays. Testosterone, E2 and E1 were measured 
by liquid chromatography-tandem mass spectrometry (LC-MS/
MS) as described (31), with limits of quantitation for testosterone 
(0.025 ng/mL), and estradiol (5 pg/mL), respectively.
Testicular ultrasonography was performed as described 
by a single experienced operator (1), and the volume of each 
testis calculated by estimating the maximal dimensions in three 
planes, excluding the epididymis, using electronic calipers and 
testis volume was calculated using the formula for a prolate 
ellipsoid (length × width × height × 0.52) (32). One value for 
length, width and height was recorded per examination, and 
testicular volume (TV) was recorded as the mean of the right 
and left testicle. Testicular echogenicity and structures within the 
scrotum were also assessed including venous diameter measured 
in the supine position with Valsalva manoeuvre. Varicocele was 
defined as present when the maximal venous diameter was over 
3 mm, and increased with the Valvalva manoeuvre (33).
Management of stored Maternal  
Blood samples
For each woman, 200 µL aliquots of the 18 and 34 week samples 
were pooled, frozen, and couriered to Copenhagen, Denmark. 
A previous pilot study confirmed stability of samples during 
prolonged storage at either −80°C or up to 15 weeks at −20°C, 
and demonstrated unaltered recovery when processed without 
acid addition before storing or after storage (34).
Phthalate Measurements
Maternal serum samples (n =  982), of which 437 were from 
women pregnant with male fetuses, were analyzed by isotope 
diluted LC-MS/MS with preceding enzymatic de-conjugation. 
The method for preparation of serum samples, standard solu-
tions and quality controls, as well as the instrumental analysis 
and general method validation was based in our previous method 
(35), and expanded to include 32 metabolites from 15 different 
phthalate diesters (Table 1; Table S1 in Supplementary Material). 
The method was modified by using online-TurboFlow-LC-MS/
MS technology equipped with a probe for heated electrospray 
ionization running in negative mode, thereby reducing sample 
volume to 100 µL. A detailed method description, validation, lim-
its of detections (LOD), linear range, matrix effects, intra-day, and 
inter-day accuracy and precision are included in Supplemental 
Materials and Methods and Tables S2–S8 in Supplementary 
Material for the entire cohort. Samples were analyzed randomly 
and blinded for the technician in 14 batches, each including cali-
bration standards, 30–40 unknown samples, three blanks, three 
serum pool controls, and three serum pool controls spiked with 
native phthalate metabolite standards at low or high level. The 
inter-day variation, expressed as the relative standard deviation 
was <20% for all analytes spiked in serum at low level except 
for MMP, MCPP, mono-iso-nonyl phthalate (MiNP), and MiDP 
TaBle 2 | Table of flow of participants through the Raine study with respect to 
availability of maternal antenatal serum for measurement of phthalates, and their 
involvement in the male reproductive assessment at 20 years of age.
all raine 
study 
participants
antenatal 
phthalates 
available
no antenatal 
phthalates 
available
Pregnant women  
enrolled in the study
2,900 982 1,918
Live births 2,868 953 1,915
Male infants 1,455 437 1,018
Female infants 1,413 516 897
Male infants 1,455 437 1,018
Participated in physical 
examination at 20 year follow-up
705 216 489
Provided blood samples 620 188 432
Participated in reproductive 
assessment
423 111 312
Provided testicular ultrasound 404 107 297
Provided semen sample 365 101 264
Participant numbers are shown for each component of the 20-year follow-up; hence 
univariable or multivariable analyses may result in marginally reduced number of 
participants due to incomplete data.
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(all ≤ 28%) and <16% for all analytes spiked at high level except 
for MiDP (20%).
Individual metabolites and their constructed sums were ana-
lyzed; MiBP and MnBP values were combined as the sum of MBP 
isomers [∑MBP(i+n)]. The metabolites mono-(2-ethylhexyl) 
phthalate (MEHP), MCMHP, and MECPP were combined as the 
sum of DEHP metabolites (∑DEHPm), and the sum of MiNP 
and MCiOP as the sum of DiNP metabolites (∑DiNPm). The 
low molecular weight phthalates MEP, MiBP, MnBP, and MHBP 
were combined (∑LMW phth.m), and the high molecular 
weight phthalates (MBzP, MEHP, MCMHP, MECPP, MCPP, 
MiNP, MCiOP and MiDP) were combined (∑HMW phth.m). 
In order to sum up the metabolites in nanograms/milliliter the 
molar concentrations of specific metabolites were calculated, 
summed, and multiplied by their respective phthalate diester 
(Table 1) (36).
statistical analysis
All phthalates metabolites values less than the limit of detection 
(<LOD) were replaced by LOD/√2 (24).
Continuous data were summarized using medians and inter-
quartile ranges (reported as Q1 −  Q3). Categorical data were 
summarized using frequency distributions. Where data had a 
non-Gaussian distribution, power transformation (Box–Cox 
analysis using Shapiro–Wilks λ as an omnibus estimate) was 
performed for TV, semen parameters, and reproductive hor-
mone data. Data ranking (five levels) based on the whole cohort 
was used for highly skewed data (phthalates and abstinence 
period). The ratio of concentrations of serum hormones LH/T 
and FSH/InhB were calculated from LH, FSH, T, and inhB raw 
measurements.
Associations between phthalate metabolites and their 
sums were performed using Pearson correlation coefficients. 
Associations between TV, semen parameters, and phthalates 
were estimated using partial correlation with adjustment for 
abstinence period, maternal smoking, varicoceles, and adjusted 
for height in analysis of associations with TV (37). Associations 
between hormone concentrations and phthalates were estimated 
using partial correlation with adjustment for BMI.
When significant correlations were found, supplementary 
Mann–Whitney tests for two independent groups were used 
for comparisons of sum of phthalates between TV grouped into 
normal (≥12.6  mL)/abnormal (<12.6 mml) (above and below 
the lowest 25th centile) and serum testosterone (above and below 
the lowest 25th centile) to examine differences in the actual 
phthalate levels.
The study explored associations between the reproductive 
outcome data and maternal phthalate metabolites without adjust-
ments for multiple testing as our tests only describe differences 
in the data, and consequently following the recommendations of 
the American Statistical Association no adjustment for multiple 
comparisons are required (38, 39). Hypothesis tests were two-
sided with p-values of <0.05 considered statistically significant 
(p values of ≤0.10 were reported when associations patterns 
across metabolites were assessed). SPSS (version 22.0, IBM SPSS) 
statistical software was used for data analysis.
resUlTs
The study cohort included 913 men who were contactable, of 
whom 753 participated in the 20-year follow-up study. Of these, 
608 completed medical questionnaires, 705 underwent physical 
examination (including 10 who only provided serum samples), 
and 423 (56% of those participating in the 20-year follow-up, 
46% of contactable men from the original cohort) participated 
in the testicular function study (Tables 2 and 3). Maternal serum 
phthalate metabolite concentrations were available for up to 216 
males within this testicular cohort overall, including up to 188 
participants with serum hormones measurements, and up to 111 
participants who also provided semen samples and/or underwent 
testicular ultrasound examination. There were no differences 
between the men with and without available maternal serum 
samples, other than they were slightly older and (of those that 
had semen for analysis) had better sperm morphology (Table 2). 
We have previously reported that the men in the Raine cohort 
who did not take part in the testicular function assessment were 
very similar to those that did agree to participate, other than 
being slightly shorter (178 vs 180 cm, p = 0.008) and having a 
lower alcohol consumption (p = 0.019) (1).
Measurement of antenatal serum 
concentrations of Phthalate Metabolites
In total 32 phthalate metabolites were determined (Table S1 
in Supplementary Material); 11 metabolites of six phthalate 
diesters were detected above LOD (Table  1). Individual 
phthalate metabolites within either the low or high molecular 
weight groups were highly correlated, as were the primary and 
secondary metabolites of DEHP and DiNP (Tables S9 and S10 
in Supplementary Material). Eight phthalate metabolites were 
detectable from more than five mothers and were included in 
further analysis (Table 4).
TaBle 3 | Anthropometric variables, lifestyle factors, and medical history of the male participants at 20 years of age—comparison between those with and without 
phthalates data available from maternal serum.
Phthalates available n = 216 Phthalates unavailable n = 489 p-Value
N Median (iQr) or N(%) N Median (iQr) or N(%)
Testicular study participation 216 111 (51.4%) 489 312 (63.8%) 0.002*
Testicular assessment 216 107 (49.5%) 489 297 (60.7%) 0.006*
Semen sample 216 101 (46.8%) 489 264 (54.0%) 0.077
general
Age (years) 216 20 (19.8–20.4) 489 19.9 (19.7–20.3) 0.002b*
Height (cm) 210 179 (173–185) 477 179 (175–184) 0.629
Height tertilea
Lowest < 176 cm 210 73 (33.8%) 477 151 (30.9%) 0.025*
Middle 57 (26.4%) 179 (36.6%)
Highest > 182 cm 80 (37.0%) 147 (30.1%)
Weight (kg) 210 77.2 (68.1–86.3) 477 75.3 (68.4–86.1) 0.859
BMI (kg/m2) 210 23.8 (21.4–26.7) 477 23.6 (21.4–26.0) 0.471
serum hormones
LH (IU/L) 185 10.6 (8.1–12.8) 423 10.4 (8.3–13.2) 0.709
FSH (IU/L) 185 4.3 (2.6–6.2) 423 4.3 (3.0–6.2) 0.288
Inhibin B (pg/mL) 185 215.4 (175.4–262.4) 423 217.2 (167.9–269.0) 0.892
Testosterone (ng/mL) 185 4.5 (3.7–6.1) 422 4.6 (3.6–5.7) 0.680
Testis volume (mean, mL) 106 15.2 (13.1–17.2) 296 14.8 (12.5–17.4) 0.802
semen parameter
Abstinence (days) 100 2 (2–3) 261 2 (2–3) 0.711
Volume (mL) 101 3 (1.9–3.8) 264 2.7 (1.9–3.7) 0.565
Sperm output (million) 101 113.4 (53.4–193.0) 264 111.5 (49.3–209.9) 0.975
Concentration (million/mL) 101 43 (20.4–75) 264 45 (22.0–69.8) 0.427
Sperm chromatin structural assay % 99 2.9 (1.8–4.8) 259 3.3 (1.8–5.4) 0.933
Morphology (normal, %) 97 6 (4–8) 257 4.5 (3–7) 0.006*
Motility (a + b, %) 101 58 (44.5–67) 260 57 (41.3–66) 0.551
Cryptorchidism 103 1 (0.5%) 292 8 (1.6%) 0.546
Herniorrhaphy 105 1 (0.5%) 291 5 (1.0%) 0.660
Varicocele/s 216 25 (11.6%) 489 77 (15.7%) 0.220
Lifestyle factorsa
Maternal smoking 216 38 (17.6%) 461 92 (18.8%) 0.467
Smoker 165 30 (13.9%) 367 54 (11.0%) 0.310
alcohol
Nil 163 24 (11.1%) 67 (13.7%) 0.530
Moderate 83 (38.4%) 186 (38.0%)
Binge 56 (12.0%) 113 (23.1%)
illicit drugs
Nil 101 73 (33.8%) 262 199 (40.7%) 0.311
Marijuana only 18 (8.3%) 32 (6.5%)
Other only 5 (2.3%) 14 (2.9%)
Marijuana and other 5 (2.3%) 17 (3.5%)
Medication
Nil 101 71 (32.9%) 262 202 (41.3%) 0.302
Non-prescription only 11 (5.1%) 24 (4.9%)
Prescription only 16 (7.4%) 32 (6.5%)
Non-prescription and prescription 3 (1.4%) 4 (0.8%)
aPercentages calculated using 489 and 216 as denominators and may not add to 100% when data are missing.
bMale participants with phthalates data available tend to be slightly older, in particular at the 95th percentile.
**p < 0.05.
LH, luteinizing hormone; FSH, follicle stimulating hormone.
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Metabolites of the high molecular weight phthalates were 
inversely associated with TV (−0.21 to −0.24, p = 0.016–0.041 
with adjustment) (Table  5). The direction of association of all 
antenatal serum phthalate metabolite concentrations with TV 
was negative for all other metabolites, apart from MEP, although 
not significant. In an unadjusted dichotomized analysis of TV 
below and above the 25th centile (12.6  mL); maternal serum 
MiNP was associated with a smaller TV: 6.0 (3.7–6.9) vs 3.9 ng/mL 
(1.9–6.2) (median and inter-quartile range respectively), p = 0.03, 
as was ∑DiNPm: 9.0 (5.4–10.5) vs 5.9 ng/mL (3.2–9.5), p = 0.05 
(Figure 1). As only two men had cryptorchidism, no association 
with phthalate exposure was apparent.
TaBle 5 | Correlations of adult testicular volume and semen parameters with maternal serum phthalate metabolites.
ranked phthalates Testis volume (ml) semen sample parameter
Volume (ml) Total sperm  
output (million)
concentration 
(million/ml)
scsa  
DFi (%)
normal  
morphology %
Motility  
(a + b grade)
MEP 0.06 −0.29** (p = 0.004) 0.03 0.18* −0.01 −0.14 0.04
MiBP −0.11 0.05 0.05 0.00 −0.07 −0.20* 0.14
MnBP −0.18* 0.04 0.04 0.00 0.05 −0.15 0.11
Mono-(2-ethylhexyl) 
phthalate
−0.16 −0.02 −0.15 −0.11 0.17* 0.15 −0.12
MECPP −0.13 −0.06 −0.08 −0.06 0.01 −0.03 −0.10
MCMHP −0.07 −0.03 −0.07 −0.05 −0.01 −0.02 −0.06
Mono-iso-nonyl  
phthalate
−0.22** (p = 0.033) 0.05 −0.10 −0.14 −0.10 −0.02 0.18*
MCiOP −0.03 −0.08 −0.09 −0.06 0.03 −0.08 −0.22** (p = 0.034)
ΣMBP (i + n) −0.19* 0.07 0.01 −0.04 0.01 −0.18* 0.11
ΣDEHPm −0.16 −0.05 −0.13 −0.10 0.15 0.08 −0.10
ΣDiNPm −0.20* 0.06 −0.08 −0.12 −0.04 −0.04 0.16
ΣDEHPm + DiNPm −0.24** (p = 0.018) 0.01 −0.14 −0.14 0.05 −0.02 0.05
ΣLMW phth.m −0.10 −0.10 0.04 0.09 0.02 −0.15 0.12
ΣHMW phth.m −0.21** (p = 0.043) 0.03 −0.12 −0.12 0.06 0.02 0.00
Σall phth.m −0.15 −0.18* −0.07 0.02 0.09 −0.15 0.05
All correlations are adjusted for abstinence period, presence of a varicocele, maternal smoking and BMI at 20 years of age. Testicular volume was also adjusted for adult height z-
scores (n = 91 to 94 for the parameters measured in adulthood).
Uncorrected p-values are shown as **p < 0.05 and *p < 0.10. No statistically significant correlations were found after adjustment for multiple comparisons (105 = 7 outcomes × 15 
phthalates) and no p-values < 0.00048 were found.
SCSA DFI, sperm chromatin structural assay DNA fragmentation index.
TaBle 4 | Phthalate metabolites (ng/mL) detected in maternal serum during pregnancy for male participants who had phthalates available (N = 216), provided blood 
samples (N = 188) and were in testicular function study (N = 111).
N = 216 N = 188 N = 111
lOD (ng/ml) % > lOD Min Median Max % > lOD Min Median Max % > lOD Min Median Max
MEP 0.65 86.1 <LOD 3.88 128.39 85.1 <LOD 3.67 128.39 84.7 <LOD 3.91 128.39
MiBP 0.75 69.4 <LOD 1.38 42.94 68.6 <LOD 1.38 42.94 73.0 <LOD 1.60 42.94
MnBP 0.61 98.1 <LOD 2.97 210.63 97.9 <LOD 2.87 210.63 97.3 <LOD 3.15 210.63
MHBPa 0.22 25.9 <LOD <LOD 2.03 25.0 <LOD <LOD 1.54 25.2 <LOD <LOD 2.03
MBzPa 0.26 31.0 <LOD <LOD 5.13 30.3 <LOD <LOD 5.13 28.8 <LOD <LOD 5.13
Mono-(2-ethylhexyl) 
phthalate
0.74 100 1.31 4.12 19.68 100 1.31 4.09 19.68 100 1.31 4.08 19.68
MECPP 0.25 100 0.27 1.06 10.84 100 0.27 1.05 10.84 100 0.28 1.16 10.84
MCMHP 0.39 99.1 <LOD 1.49 16.53 98.9 <LOD 1.50 16.53 100 0.45 1.55 16.53
MCPPa 0.19 43.1 <LOD <LOD 7.58 45.2 <LOD <LOD 7.58 45.0 <LOD <LOD 7.58
Mono-iso- 
nonyl phthalate
0.53 97.2 <LOD 3.94 14.06 97.3 <LOD 4.14 14.06 97.3 <LOD 4.28 14.06
MCiOP 0.13 68.1 <LOD 0.18 15.28 68.6 <LOD 0.18 15.28 73.9 <LOD 0.20 4.12
ΣMBP(i + n) <LOD 4.42 253.57 <LOD 4.33 253.57 <LOD 5.08 253.57
ΣDEHPm 2.89 9.86 51.46 2.89 9.69 51.46 4.14 9.85 51.46
ΣDiNPm <LOD 5.87 28.07 <LOD 6.43 28.04 <LOD 6.48 20.54
ΣDEHPm + DiNPm 2.67 11.46 38.61 2.67 11.46 38.61 4.25 11.95 38.61
ΣLMW phth.m <LOD 8.91 241.12 <LOD 8.41 241.12 <LOD 8.93 241.12
ΣHMW phth.m 3.81 12.15 38.61 3.81 12.15 38.61 4.25 12.46 38.61
Σall phth.m 9.46 25.17 354.43 9.46 24.77 354.43 9.46 25.49 354.43
aDue to low numbers of detectable samples these are no longer used in subsequent analysis, except for the relevant sums.
LOD, limit of detection.
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Seminal volume was negatively associated with antenatal 
serum concentration of MEP (−0.29, p  =  0.003), and sperm 
motility with MCiOP concentration (−0.22, p =  0.033), after 
adjustment for abstinence period, presence of a varicocele, mater-
nal smoking and BMI at 20 years of age, in addition TV was also 
adjusted for adult height (Table 5), but not after adjustment for 
multiple comparisons. No other systematic or significant associa-
tions of antenatal serum concentrations of phthalate metabolites 
with semen parameters were noted, although the direction of 
all associations of sperm concentration with antenatal serum 
phthalate metabolite concentrations were negative, apart from 
MEP (Table 5).
TaBle 6 | Pearson correlation coefficients between serum hormones and maternal serum phthalate metabolites for 188 male participants, adjusting for BMI at 20 years 
of age (n = 172).
lh (iU/l) Fsh (iU/l) inhB (pg/ml) Testosterone (ng/ml) lh:T Fsh:inhB e1 (nmol/l) e2 (nmol/l)
MEP 0.04 0.06 0.01 0.04 0.00 0.00 −0.11 −0.04
MiBP 0.04 −0.01 −0.07 −0.04 0.06 0.01 −0.04 0.05
MnBP −0.01 −0.03 −0.01 −0.07 0.05 −0.03 −0.10 −0.02
Mono-(2-ethylhexyl)  
phthalate
0.06 0.11 0.02 0.26** (p = 0.0005) −0.19** (p = 0.01) 0.06 0.05 0.01
MECPP 0.12 0.01 0.03 −0.02 0.10 0.03 0.01 0.08
MCMHP 0.11 0.04 0.05 −0.05 0.13* 0.02 −0.01 0.08
Mono-iso-nonyl  
phthalate
0.11 0.14** (p = 0.0495) −0.12 0.18** (p = 0.01) −0.08 0.14* 0.02 0.02
MCiOP −0.04 −0.04 0.02 0.03 −0.06 −0.03 −0.07 0.00
ΣMBP (i + n) 0.01 −0.02 −0.05 −0.10 0.08 −0.01 −0.08 0.00
ΣDEHPm 0.15** (p = 0.048) 0.09 0.08 0.21** (p = 0.006) −0.07 0.04 0.06 0.05
ΣDiNPm 0.09 0.12 −0.13 0.18** (p = 0.02) −0.08 0.12 0.01 0.00
ΣDEHPm + DiNPm 0.13* 0.09 −0.03 0.24** (p = 0.001) −0.11 0.06 0.06 0.03
ΣLMW phth.m 0.06 0.03 0.01 0.06 −0.01 −0.03 −0.07 −0.01
ΣHMW phth.m 0.10 0.10 −0.01 0.20** (p = 0.0076) −0.10 0.07 0.04 0.04
Σall phth.m 0.09 0.06 −0.04 0.11 −0.04 0.05 −0.03 0.05
Uncorrected p-values are shown as **p < 0.05 and *p < 0.10. No statistically significant correlations were found after adjustment for multiple comparisons.
(120 = 8 outcomes × 15 phthalates) and no p-values < 0.00042 were found.
LH, luteinizing hormone; FSH, follicle stimulating hormone; T, testosterone; inhB, inhibin B; E1, estradiol; E2, estrone.
Ratio of concentrations of serum hormones LH/T and FSH/InhB were calculated from LH, FSH, T, and inhibin raw values.
Power transformation was performed for LH, FSH, inhB, Testosterone, E1, and E2.
Natural logarithmic transformation was performed for LH:T ratio. Ranking into five groups performed for FSH:InhB ratio.
FigUre 1 | Association of prenatal maternal serum phthalates (nanograms/milliliter) with testicular volume (milliliter) in their adult sons.
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After adjustment for BMI, there were significant positive asso-
ciations between serum total testosterone concentrations (all 
p < 0.05) and antenatal serum phthalate metabolite concentra-
tions of MEHP, MiNP, ∑DEHPm, ∑DiNPm, ∑HMW phth.m, 
and ∑DEHPm + DiNPm (Table 6), but not after adjustment for 
multiple comparisons. In an unadjusted dichotomized analysis 
of adult serum testosterone above and below the 25th centile 
(3.69  ng/mL), a higher maternal serum MEHP was associated 
with a higher adult serum testosterone concentration: 4.5 
(2.8–6.3) vs 3.0  ng/mL (2.3–4.4) (median and inter-quartile 
range), p = 0.001, as was ∑DEHPm 10.3 (7.4–12.6) vs 8.0 ng/mL 
(3.1–11.7), p = 0.02 (Figure 2). After adjustment for current BMI, 
a positive correlation between serum FSH level and maternal 
serum MiNP concentration (0.14, p = 0.049), and serum LH levels 
and maternal serum ∑DEHPm (0.15, p = 0.048) was noted, and 
a negative association of the serum LH to testosterone ratio with 
antenatal MEHP concentration (0.19, p  =  0.0137) (Table  6). 
No associations between antenatal serum phthalate metabolite 
FigUre 2 | Association of prenatal maternal serum phthalates (nanograms/milliliter) with total serum testosterone (nanograms/milliliter) in their adult sons.
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concentrations and adult male serum inhB, E1, or E2 concentra-
tions were found.
DiscUssiOn
This is the first human cohort study to assess whether antenatal 
serum concentrations of a large range of phthalate metabolites 
have an association with male reproductive health in early adult-
hood. We have previously reported within the same cohort that 
maternal bisphenol A exposure appeared to have no adverse 
effect of testicular function in adulthood (40). Our data identi-
fied a potential association between DEHP and DiNP and 
TV as well as total serum testosterone. We found a potential 
positive association between serum FSH concentration and 
antenatal serum concentration of MiNP, but this was not sup-
ported by other DiNP metabolites or any other phthalates, and 
hence may be a chance finding. Also no effects were evident of 
serum phthalate metabolites on adult serum inhB or estrogen 
concentrations. Thus, hormonal associations of antenatal serum 
phthalate metabolite concentrations were most systematically 
observed for the LH-testosterone axis. However, given the sample 
size, potential confounding with additional postnatal exposures 
and multiplicity of comparisons, further corroboration of these 
findings is warranted.
Evidence from human and animal studies suggests that our 
study observations may not be a chance finding. Cross-sectional 
studies of adult men have demonstrated that current phthalate 
exposure, as determined by urinary phthalate metabolite excre-
tion, was associated with subtle negative influences in sperm 
counts and reproductive hormones (41–43). Subtle associations 
were demonstrated between phthalate monoester levels in breast 
milk and reproductive hormones in 3-month-old boys, by an 
increase in the LH: free testosterone ratio and a decrease in free 
testosterone (19). Phthalates not only affect the hypothalamus-
pituitary gonadal axis but also have shown to be associated 
with serum levels of growth factors and thyroid hormone (44), 
which in consequence may affect SHBG levels. These complex 
interactions on several hormone axes in humans may explain the 
apparent contradiction of results concerning TV and total testos-
terone in our study. In addition the anogenital distance, which 
represents an integrated measure of androgen action in humans 
and rodents, was negatively associated with maternal phthalate 
exposure during pregnancy (21, 45). First trimester exposures to 
DBP and high molecular weight phthalates have been correlated 
with a reduction in maternal free testosterone and an increase in 
estrogen (46).
Our data are in agreement with some studies in rats which 
showed that antenatal exposures to phthalates resulted in 
inhibition of steroidogenesis in Leydig cells leading to devel-
opment of clinical and histological features similar to TDS in 
humans. The susceptibility of the rodent testicle to phthalates 
maybe more pronounced than in the human, and partially 
reversible (47–49). On the other hand, human exposures are 
life-long and the patterns of exposures vary with time (50) (see 
text footnote 1).
Our findings should be viewed cautiously as the study has 
several important limitations. First, as this is an observational 
study causality cannot be proven, and we are unable to account 
for any additional postnatal environmental exposures, which may 
contribute to the findings (51). Hence, our hypothesis generation 
lies in the observation that some reproductive parameters showed 
the same direction of associations with several or all phthalate 
metabolites. The observed inter-relation of phthalate metabolites 
is also relevant as phthalates may act additively or synergistically 
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(14, 15). It is proposed that phthalates may exert their endocrine-
disrupting effects by inhibition of testosterone and estradiol 
synthesis (14, 15, 16, 52, 53), aromatase activity inhibition (54), 
alterations in estrogen metabolism (55–57), and prostaglandin 
synthesis (58).
A major disadvantage of our study was that only maternal 
serum samples, and not urine, were available for exposure assess-
ment. This limits the sensitivity of the study (35), as demonstrated 
by the finding that only 11 of a potential 32 metabolites were 
detectable in the serum samples, and only eight were present with 
a frequency sufficient to be used within the analyses. However, 
given the paucity of the data from human studies, particularly 
related adult outcomes of antenatal exposures to current envi-
ronmental chemicals, we believe that our data are relevant and 
should stimulate further research in this area, and if possible by 
analyzing maternal urine samples.
It is known that the enzymes involved in hydrolysis of diester 
phthalates to monoesters are present in blood (59), and may 
lead to falsely elevated monoester levels after blood sampling 
if contamination occurs during handling and storage (60). 
Thus, secondary metabolites are a more reliable measure of 
true exposure, but they only exist for high molecular weight 
phthalates. Our laboratory has previously performed a series of 
pilot studies to ensure that the results of the phthalate analysis 
of such samples were robust and likely to reflect true phthalate 
exposure at time of collection (34). In addition, diester contami-
nation is likely to have been relatively minor, since we observed 
a large inter-individual variation for the first step metabolites, 
rather than generally high concentrations within the samples. 
Additionally, it is important to recognize the strong positive 
correlation between the serum concentrations of the first and 
second step metabolites of DEHP and DiNP which corroborates 
our interpretation that the reported MEHP and MiNP concen-
trations reflect true exposure.
Few previous studies have reported concentrations of 
phthalate metabolites in serum. The levels of some phtha-
late metabolites in the present study are in accordance with 
serum levels observed in others. Median concentrations of 
MECPP (1.6 ng/mL) and MCiOP (0.2 ng/mL) in men from 
Greenland, Poland and Ukraine 2002–2004 were comparable 
to our observations (61). Median levels of MEP (4.1  ng/mL) 
and MEHP (5.4  ng/mL) from American adults (NHANES 
1999–2000) and MEHP (4.3–4.7 ng/mL) in a Swedish popula-
tion were also similar to our data (62, 63). In contrast, another 
Danish study of young men found lower levels of MECPP 
(0.52  ng/mL) and higher levels of MEHP (7.9  ng/mL) (35). 
The median serum level of all other common phthalate 
metabolites in the Danish study was below the LOD, while 
the Swedish study reported higher MEP (11.6  ng/mL) and 
MiBP (13.4  ng/mL) and the American study higher MnBP 
(14.4  ng/mL) compared to our data. Despite the potential 
collection and storage limitations, we thus believe that similar 
phthalate levels measured in this and other studies are likely 
to accurately reflect concentrations at the time of collection 
and true exposure.
In summary, this longitudinal study is the first to explore poten-
tial associations between antenatal serum phthalate metabolite 
concentrations and the reproductive function of young men, in 
particular with respect to TV and Leydig cell function. Although 
our findings are of borderline significance, and our study is small, 
they are plausible and consistent with numerous experimental 
data and require corroboration. However, due to the study’s 
limitations, the findings should be viewed with caution until con-
firmatory data are available from larger, prospectively designed 
cohort studies.
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